Paper39102176
Examining the Effect of Missing Data and Unmeasured Confounding on External Comparator Studies: Case Studies and Simulations.
Rippin G and 10 others. Drug Saf, 2024. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Examining the Effect of Missing Data and Unmeasured Confounding on External Comparator Studies: Case Studies and Simulations. Papers, record 39102176. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39102176
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Examining the Effect of Missing Data and Unmeasured Confounding on External Comparator Studies: Case Studies and Simulations.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Prostatic Neoplasms | Major topic |
| Multiple Myeloma | Major topic |
| Randomized Controlled Trials as Topic | Major topic |
| Computer Simulation | Major topic |
| Bias | Major topic |
| Humans | |
| Male | |
| Confounding Factors, Epidemiologic | |
| Research Design | |
| Sample Size | |
| Data Interpretation, Statistical |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| EMA/2017/09/PE | European Medicines Agency | PubMed | ||
| Lot 4 | European Medicines Agency | PubMed |
Source PubMed
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32440224 | Synthetic and External Controls in Clinical Trials - A Primer for Researchers. | Clin Epidemiol | 2020 | https://conductscience.org/library/papers/32440224 | PubMed |
| 2 | 31335166 | An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer. | JCO Clin Cancer Inform | 2019 | https://conductscience.org/library/papers/31335166 | PubMed |
| 3 | 30878639 | The proportion of missing data should not be used to guide decisions on multiple imputation. | J Clin Epidemiol | 2019 | https://conductscience.org/library/papers/30878639 | PubMed |
| 4 | 29207961 | When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts. | BMC Med Res Methodol | 2017 | https://conductscience.org/library/papers/29207961 | PubMed |
| 5 | 30636285 | Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making. | Clin Pharmacol Ther | 2019 | https://conductscience.org/library/papers/30636285 | PubMed |
| 6 | 34014439 | The Use of External Controls in FDA Regulatory Decision Making. | Ther Innov Regul Sci | 2021 | https://conductscience.org/library/papers/34014439 | PubMed |
| 7 | 30987939 | Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. | Lancet Oncol | 2019 | https://conductscience.org/library/papers/30987939 | PubMed |
| 8 | 32440847 | A Framework for Methodological Choice and Evidence Assessment for Studies Using External Comparators from Real-World Data. | Drug Saf | 2020 | https://conductscience.org/library/papers/32440847 | PubMed |
| 9 | 35895225 | A Review of Causal Inference for External Comparator Arm Studies. | Drug Saf | 2022 | https://conductscience.org/library/papers/35895225 | PubMed |
| 10 | 31350853 | Using Electronic Health Records to Derive Control Arms for Early Phase Single-Arm Lung Cancer Trials: Proof-of-Concept in Randomized Controlled Trials. | Clin Pharmacol Ther | 2020 | https://conductscience.org/library/papers/31350853 | PubMed |
| 11 | 29059439 | Real-world Data for Clinical Evidence Generation in Oncology. | J Natl Cancer Inst | 2017 | https://conductscience.org/library/papers/29059439 | PubMed |
| 12 | 40980106 | External Comparator Cohort studies - clarification of terminology. | Front Drug Saf Regul | 2023 | https://conductscience.org/library/papers/40980106 | PubMed |
| 13 | 33908160 | The use of external controls: To what extent can it currently be recommended? | Pharm Stat | 2021 | https://conductscience.org/library/papers/33908160 | PubMed |
| 14 | 37097356 | Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses: Results of 32 Clinical Trials. | JAMA | 2023 | https://conductscience.org/library/papers/37097356 | PubMed |
| 15 | 30257058 | Closed-form variance estimator for weighted propensity score estimators with survival outcome. | Biom J | 2018 | https://conductscience.org/library/papers/30257058 | PubMed |
| 16 | 31541454 | Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project. | Clin Pharmacol Ther | 2020 | https://conductscience.org/library/papers/31541454 | PubMed |
| 17 | 30819708 | Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review. | BMJ Open | 2019 | https://conductscience.org/library/papers/30819708 | PubMed |
| 18 | 31063192 | Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. | Am J Epidemiol | 2019 | https://conductscience.org/library/papers/31063192 | PubMed |
| 19 | 29944008 | Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib. | J Comp Eff Res | 2018 | https://conductscience.org/library/papers/29944008 | PubMed |
| 20 | 30031168 | The use of real-world data in cancer drug development. | Eur J Cancer | 2018 | https://conductscience.org/library/papers/30031168 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41669939 | Assessing Overall Survival Benefits in Advanced Cancers: The Role of External Comparator Cohort Studies with Real-World Data. | Clin Pharmacol Ther | 2026 | https://conductscience.org/library/papers/41669939 | PubMed |
| 41021206 | Choosing an Index Date for Untreated Patients in External Comparator Studies. | Drug Saf | 2026 | https://conductscience.org/library/papers/41021206 | PubMed |
| 40979390 | External comparator studies and the joint application of the estimand and target trial emulation frameworks. | Front Drug Saf Regul | 2024 | https://conductscience.org/library/papers/40979390 | PubMed |
| 40835783 | External Comparator Studies: Performance of Four Missing Data-Handling Approaches, Stratified by Four Different Marginal Estimators. | Drug Saf | 2025 | https://conductscience.org/library/papers/40835783 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39102176
GET https://conductscience.org/api/papers/v1/39102176/references?page=2